The 17 most recent market catalysts affecting $AXSM, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 23, 2026
Corporate Catalyst
Bullish
Impact 65
Truist Securities Maintains Buy on Axsome Therapeutics, Raises Price Target to $285
Truist Securities analyst Srikripa Devarakonda maintained a 'Buy' rating on Axsome Therapeutics and raised the price target from $200 to $285. This substantial increase in the pric…
Sep 18, 2026
Corporate Catalyst
Neutral
Impact 55
Piper Sandler Reiterates Overweight on Axsome Therapeutics, Maintains $258 Price Target
Piper Sandler analyst David Amsellem has reaffirmed an 'Overweight' rating and a $258 price target for Axsome Therapeutics. This action signals continued confidence in the company'…
Sep 17, 2026
Corporate Catalyst
Neutral
Impact 75
Axsome Therapeutics Announces Presentation Of New Data In Major Depressive Disorder And Alzheimer's Disease Agitation At Psych Congress 2026
The announcement of new data presentations for major depressive disorder and Alzheimer's disease agitation at a prominent medical congress is a significant corporate catalyst for A…
Aug 31, 2026
Corporate Catalyst
Neutral
Impact 55
HC Wainwright & Co. Reiterates Buy on Axsome Therapeutics, Maintains $290 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating and maintained a $290 price target for Axsome Therapeutics. This action signals continued confidence fr…
Aug 12, 2026
Corporate Catalyst
Bullish
Impact 55
Mizuho Maintains Outperform on Axsome Therapeutics, Raises Price Target to $316
Mizuho analyst Graig Suvannavejh has maintained an 'Outperform' rating on Axsome Therapeutics and raised the price target from $306 to $316. This action signals continued confidenc…
Aug 11, 2026
Corporate Catalyst
Bullish
Impact 55
Morgan Stanley Maintains Equal-Weight on Axsome Therapeutics, Raises Price Target to $251
Morgan Stanley analyst Sean Laaman raised the price target for Axsome Therapeutics (AXSM) from $242 to $251, while keeping an 'Equal-Weight' rating. This adjustment reflects a slig…
Aug 11, 2026
Corporate Catalyst
Bearish
Impact 55
RBC Capital Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $297
RBC Capital's analyst Leonid Timashev maintained an 'Outperform' rating for Axsome Therapeutics, signaling continued confidence in the company's long-term potential. However, the p…
Aug 11, 2026
Corporate Catalyst
Bearish
Impact 75
Axsome Therapeutics Analysts Increase Their Forecasts Following Q2 Results
Axsome Therapeutics (AXSM) reported a Q2 earnings per share loss of 99 cents and sales of $218.4 million, both missing analyst expectations. Despite these 'downbeat results,' the c…
Aug 11, 2026
Corporate Catalyst
Bullish
Impact 55
Guggenheim Maintains Buy on Axsome Therapeutics, Raises Price Target to $275
Guggenheim analyst Yatin Suneja has maintained a 'Buy' rating on Axsome Therapeutics and raised the price target from $260 to $275. This action signals a strengthened conviction fr…
Aug 11, 2026
Corporate Catalyst
Bullish
Impact 55
Wells Fargo Maintains Overweight on Axsome Therapeutics, Raises Price Target to $256
Wells Fargo analyst Benjamin Burnett maintained an 'Overweight' rating on Axsome Therapeutics and raised the price target by a modest $1, from $255 to $256. This action signals con…
Aug 11, 2026
Corporate Catalyst
Bullish
Impact 55
Needham Maintains Buy on Axsome Therapeutics, Raises Price Target to $268
Needham analyst Ami Fadia maintained a 'Buy' rating on Axsome Therapeutics (AXSM) and raised the price target from $267 to $268. This action signals continued analyst confidence in…
Aug 10, 2026
Corporate Catalyst
Bearish
Impact 92
Axsome Therapeutics Q2 EPS $(0.99) Misses $(0.83) Estimate, Sales $218.400M Miss $221.230M Estimate
Axsome Therapeutics' Q2 earnings report indicates a substantial miss on profitability, with EPS significantly below analyst expectations and a more than doubling of losses compared…
Jul 31, 2026
Corporate Catalyst
Bearish
Impact 55
Axsome Therapeutics shares are trading lower after Mizuho lowered its price target on the stock from $310 to $306.
This headline directly impacts Axsome Therapeutics (AXSM) as an analyst firm, Mizuho, has lowered its price target. While the reduction from $310 to $306 is relatively small (appro…
Jul 31, 2026
Corporate Catalyst
Bearish
Impact 55
Mizuho Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $306
Mizuho analyst Graig Suvannavejh maintained an 'Outperform' rating on Axsome Therapeutics, signaling continued positive sentiment towards the company. However, the price target was…
Jul 21, 2026
Corporate Catalyst
Bullish
Impact 75
Axsome Therapeutics shares are trading higher after BMO Capital initiated its coverage on the stock with an Outperform rating and announced a price target of $310.
This headline represents a significant corporate catalyst for Axsome Therapeutics. An 'Outperform' rating from a reputable firm like BMO Capital, coupled with a substantial price t…
Jul 21, 2026
Corporate Catalyst
Neutral
Impact 65
BMO Capital Initiates Coverage On Axsome Therapeutics with Outperform Rating, Announces Price Target of $310
BMO Capital's initiation of coverage on Axsome Therapeutics with an 'Outperform' rating and a $310 price target is a positive development for the company. Analyst coverage, especia…
Jul 15, 2026
Corporate Catalyst
Neutral
Impact 55
HC Wainwright & Co. Reiterates Buy on Axsome Therapeutics, Maintains $290 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating and maintained a $290 price target for Axsome Therapeutics. This action signals continued confidence fr…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.